Main Menu

Centre for Cancer Drug Discovery

The Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research, London, is the largest academic cancer drug discovery and development group worldwide. Its research teams cover every aspect of new drug discovery and development, from cell and molecular biology through to chemical synthesis of new agents and their evaluation in clinical trials.

The ICR is currently making a significant investment in the Division of Cancer Therapeutics – which encompasses the Centre for Cancer Drug Discovery – with the recruitment of five new senior Faculty including roles in the Centre for Cancer Drug Discovery, the new Centre for Protein Degradation and the new Centre for Target Validation.

Current senior CCDD vacancies

The mission of the Centre for Cancer Drug Discovery is:

  • To discover and develop effective therapeutics for the treatment of cancer
  • Exploit the addictions, dependencies and vulnerabilities of cancer cells to develop innovative small molecule drugs
  • Prioritise novelty and unmet clinical need in defined patient populations.

Centre for Cancer Drugs Discovery building

Image: The Centre for Cancer Drug Discovery is based in a state-of-the-art £75m building on our Sutton campus, opened in 2020.

Since 2005, research teams now based in the Centre for Cancer Drug Discovery have:

  • Discovered 21 clinical candidates
  • Of which 13 have entered clinical trials

See our therapeutic pipeline

The ICR also discovered abiraterone, which was approved by NICE in 2012, and is widely used to treat advanced prostate cancer across the world.

Find out more about the Centre for Cancer Drug Discovery

Teams and team leaders

Find out which teams and team leaders make up our Centre for Cancer Drug Discovery.

Find out more